Ryvu Therapeutics S.A. reported earnings results for the full year ended December 31, 2023. For the full year, the company reported sales was PLN 46.86 million compared to PLN 38.95 million a year ago. Revenue was PLN 67.3 million compared to PLN 68.44 million a year ago.

Net loss was PLN 92.11 million compared to PLN 83.78 million a year ago. Basic loss per share from continuing operations was PLN 4.02 compared to PLN 4.56 a year ago. Diluted loss per share from continuing operations was PLN 4.02 compared to PLN 4.56 a year ago.